MK-1406 with Fluzone High-Dose vaccine in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, double-blind, randomized trial to see if MK-1406 affects the immune response to Fluzone High-Dose vaccine and to assess safety when given together in healthy participants. Participants are randomly assigned to receive MK-1406 or placebo with Fluzone HD, and both groups are monitored for immune responses and adverse events. The study will measure immunogenicity outcomes and safety/tolerability across a controlled, closely supervised setting. Eligible participants are adults 18–49 who are generally healthy and have not recently received a seasonal flu vaccine or had influenza. The trial is conducted at two sites in the United States and led by Cidara Therapeutics in collaboration with Merck & Co.

Why it matters

Who can join: the full rules

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Be ≥18 to ≤49 years of age
* Be deemed healthy by the Investigator
* Have not received any seasonal influenza vaccine and have not had a diagnosed or suspected influenza infection within 12 months prior to Day 1 of the trial

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Had an active malignancy within 5 years prior to screening, except basal cell or squamous cell skin cancer. Any history of breast cancer or melanoma is exclusionary.
* Has previously been diagnosed with Guillain-Barre Syndrome following a previous influenza vaccination.

Where it's running

• Parexel ( Site 0001)
  Glendale, California, United States Recruiting
• Parexel ( Site 0002)
  Baltimore, Maryland, United States Recruiting

Study contacts

• Study coordinator: Toll Free Number
• Email: Trialsites@msd.com
• Phone: 1-888-577-8839

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How age affects germinal center responses after flu and rabies vaccines

  Researchers will test how the immune system responds to flu and rabies vaccines in younger adults (18–40) and older adults (65+).

  Recruiting Phase 4 Washington University School of Medicine · St Louis, Missouri · NCT07914673

• Magnetic field maps with NV sensors for non-invasive heart measurements

  This study tests whether diamond-based NV magnetometers can non-invasively detect and map the heart's magnetic field in healthy adults.

  Recruiting Robert Bosch GmbH · Renningen · NCT07908173

• Methylation analyses using home-based self-sampling in women with and without gynecological disease

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation markers that distinguish people with gynecological (pre-)cancers from cancer-free controls.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902388

• Omega-3 status in healthy adults: comparing different fish-oil and algae-oil products

  This study tests whether various fish-oil and algae-oil products can raise the Omega-3 Index in healthy adults who don’t eat much fatty fish.

  Recruiting Nordic Naturals · London, Ontario · NCT07900425

• A safe, carefully dosed test of TBD11 in healthy adults

  This phase 1 study tests TBD11 in healthy adults to see if it is safe and tolerable and to understand how it behaves in the body, including how it interacts with other medicines.

  Recruiting Phase 1 Gates Medical Research Institute · Bloemfontein · NCT07883226

• Fosmanogepix in healthy adults: how it may interact with other drugs and heart rhythm

  This study tests whether fosmanogepix (and its active form manogepix) changes how other medicines work in healthy adults.

  Recruiting Phase 1 Basilea Pharmaceutica · Groningen, Netherlands · NCT07881224

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.